» Articles » PMID: 38434933

Hepatitis C Attributable Healthcare Costs and Mortality Among Immigrants: A Population-Based Matched Cohort Study

Overview
Specialty Gastroenterology
Date 2024 Mar 4
PMID 38434933
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario, Canada.

Methods: We conducted a population-based matched cohort study among immigrants diagnosed with CHC between May 31, 2003, and December 31, 2018, using linked health administrative data. Immigrants with CHC (exposed) were matched 1 : 1 to immigrants without CHC (unexposed) using a combination of hard (index date, sex, and age) and propensity-score matching. Net costs (2020 Canadian dollars) collected from the healthcare payer perspective were calculated using a phase-of-care approach and used to estimate long-term costs adjusted for survival.

Results: We matched 5,575 exposed individuals with unexposed controls, achieving a balanced match. The mean age was 47 years, and 52% was male. On average, 10.5% of exposed and 3.5% of unexposed individuals died 15 years postindex (relative risk = 2.9; 95% confidence interval (CI): 2.6-3.5). The net 30-day costs per person were $88 (95% CI: 55 to 122) for the prediagnosis, $324 (95% CI: 291 to 356) for the initial phase, $1,016 (95% CI: 900 to 1,132) for the late phase, and $975 (95% CI: -25 to 1,974) for the terminal phase. The mean net healthcare cost adjusted for survival at 15 years was $90,448.

Conclusions: Compared to unexposed immigrants, immigrants infected with CHC have higher mortality rates and greater healthcare costs. These findings will support the planning of HCV elimination efforts among key risk groups in the province.

References
1.
Austin P . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010; 10(2):150-61. PMC: 3120982. DOI: 10.1002/pst.433. View

2.
Erman A, Wong W, Feld J, Grootendorst P, Krahn M . The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int. 2019; 40(1):51-59. DOI: 10.1111/liv.14247. View

3.
Wong W, Haines A, Bremner K, Yao Z, Calzavara A, Mitsakakis N . Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open. 2021; 9(1):E167-E174. PMC: 8034296. DOI: 10.9778/cmajo.20200162. View

4.
Krajden M, Kuo M, Zagorski B, Alvarez M, Yu A, Krahn M . Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol. 2010; 24(12):717-26. PMC: 3004444. DOI: 10.1155/2010/569692. View

5.
de Oliveira C, Pataky R, Bremner K, Rangrej J, Chan K, Cheung W . Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016; 16(1):809. PMC: 5070134. DOI: 10.1186/s12885-016-2835-7. View